Abstracts tagged "population studies"

Abstract Number: 1122 • ACR Convergence 2020
Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review
Jove Graham¹, Tonia Novosat¹, Haiyan Sun¹, Brian Piper², Joseph Boscarino¹, Melissa Kern¹, Vanessa Duboski³, Eric Wright³, Patricia Schepman⁴, Rebecca Robinson⁵, Edward Casey⁶, Craig Beck⁷ and Jerry Hall⁸, ¹Geisinger, Danville, ²Geisinger, Scranton, ³Geisinger, Forty Fort, ⁴Pfizer, New York City, NY, ⁵Eli Lilly and Company, Indianapolis, ⁶Pfizer, New York, ⁷Pfizer, London, ⁸Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Osteoarthritis (OA) is a mechanically and immunologically mediated common disease with a complex pathogenesis. Despite epidemiologic studies proving increasing age, obesity and female gender…
Abstract Number: 0491 • ACR Convergence 2020
Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
Lauren C. Prisco¹, Matthew Moll¹, Jiaqi Wang², Weixing Huang³, Lily Martin¹, Vanessa Kronzer⁴, Sicong Huang², Edwin Silverman², Tracy J. Doyle⁵, Michael Cho⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Mayo Clinic, Rochester, MN, ⁵Brigham and Women's Hospital, West Roxbury, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Established pulmonary manifestations of RA include restrictive processes such as interstitial lung disease and obstructive processes such as bronchiectasis, but clinically detected forms of…
Abstract Number: 1476 • ACR Convergence 2020
Trends in Mortality and Cause-specific Mortality Among Patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada
Keith Colaco¹, Jessica Widdifield², Jin Luo³, Cheryl Rosen⁴, Raed Alhusayen⁵, J. Michael Paterson⁶, Willemina Campbell⁷, Karen Tu⁴, Sasha Bernatsky⁸, Dafna Gladman⁹ and Lihi Eder¹⁰, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³ICES, Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, ⁶ICES, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, ON, Canada, ⁸The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ⁹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁰Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Several studies have consistently demonstrated that psoriasis is associated with an increased risk of mortality compared to the general population. However, the excess risk…
Abstract Number: 0517 • ACR Convergence 2020
Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study
Thomas Garvey¹, Cynthia Crowson², Matthew J. Koster³ and Kenneth Warrington³, ¹Mayo Clinic Rochester, Apple Valley, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Diagnostic methods for giant cell arteritis (GCA) have evolved over recent decades, and large vessel imaging plays an increasing role in disease detection. The…
Abstract Number: 1570 • ACR Convergence 2020
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology
Amy Cunningham-Bussel¹, Jiaqi Wang¹, Lauren C. Prisco², Lily Martin², Lydia Gedmintas¹, Lindsey Macfarlane¹, Nancy Shadick¹, Mark Awad³, Osama Rahma³, Nicole LeBoeuf³, Ellen Gravallese¹ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Dana-Farber Cancer Institute, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) are used to treat an expanding number of cancers. Many cancer patients treated with ICI develop immune-related adverse events (irAE)…
Abstract Number: 0540 • ACR Convergence 2020
Risk of Hydroxychloroquine Retinopathy in the Community
Jesse Dabit¹, Mehmet Hocaoglu², Kevin Moder¹, Andrew Barkmeier³, Wendy Smith³, Thomas O'Byrne¹, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Hydroxychloroquine (HCQ) is used in the treatment of a wide variety of autoimmune diseases. HCQ retinopathy is a feared complication of long-term use. The…
Abstract Number: 2036 • ACR Convergence 2020
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
Ariane Barbacki¹, Murray Baron², Mianbo Wang³, Yuqing Zhang⁴, Mandana Nikpour⁵ and Ada Man⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²Jewish General Hospital, Montreal, QC, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, ⁵The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, ⁶University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality and characterized by the accrual of organ damage over time.…
Abstract Number: 058 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis
Cal Robinson ¹, Rahul Chanchlani ¹, Megan Schlorff ¹, Francis Lao ¹, Tapas Mondal ¹, Catherine Demers ¹, Elizabeth Darling ¹, Sandeep Brar ², Rulan Parekh ³, Hsien Seow ¹, Eric Benchimol ⁴ and Michelle Batthish¹, ¹McMaster University, Hamilton, Canada, ²University of California, San Fransisco, ³University of Toronto, Toronto, Canada, ⁴University of Ottawa, Ottawa, Canada
Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed…
Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Aladdin Mohammad¹, Pavlos Stamatis ¹ and Aleksandra Turkiewicz ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…
Abstract Number: 893 • 2019 ACR/ARP Annual Meeting
The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjögren Syndrome
Petra Yntema-Eckenhaussen ¹, Suzanne Arends ¹, Elisabeth Brouwer ², Caroline Roozendaal ³, Hendrika Bootsma ⁴, Johanna Westra ¹ and Karina de Leeuw¹, ¹Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Dept. of Laboratory Medicine - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ⁴University of Groningen, Groningen, Netherlands
Background/Purpose: Previous studies have demonstrated that years before clinical onset of auto-immune diseases, auto-antibodies can already be present. However, it is also known that some…
Abstract Number: 2084 • 2019 ACR/ARP Annual Meeting
Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017
Kristina Theis¹, Michael Boring ² and Ross Wilkie ³, ¹Centers for Disease Control and Prevention, Atlanta, ²Johnson Consulting dba Cutting Edge Technologies and Solutions, Atlanta, ³Keele University, Keele, United Kingdom
Background/Purpose: “Arthritis-attributable activity limitation” (AAAL) is linked to many potentially modifiable characteristics (e.g., work disability, physical inactivity, obesity). By 2015, prevalence of AAAL among adults…
Abstract Number: 2189 • 2019 ACR/ARP Annual Meeting
Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population
Marieke Loef¹, Féline PB Kroon ¹, Stephan Böhringer ¹, Frits R Rosendaal ¹ and Margreet Kloppenburg ¹, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Background/Purpose: The Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire is a widely used patient-reported outcome tool, developed to evaluate short- and long-term knee symptoms…
Abstract Number: 1588 • 2018 ACR/ARHP Annual Meeting
Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia
Julia Tan¹, J. Antonio Avina-Zubieta², Alyssa Dominique³, Hamid Tavakoli⁴ and Teresa A Simon³, ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic…
Abstract Number: 2417 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Systemic Lupus Erythematous and Pre-Systemic Lupus Erythematous: A Population-Based Cohort Study
A. Nicole Wade¹, Mary A. De Vera², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The adverse effects of systemic lupus erythematosus (SLE) on maternal and fetal outcomes in pregnancy have been explored mainly in clinic-based cohorts. However, data…
Abstract Number: 2954 • 2018 ACR/ARHP Annual Meeting
Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Yinzhu Jin¹, Eun Ha Kang², Angela Tong¹, Rishi J. Desai³ and Seoyoung C. Kim^4,5, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: While efficacy of triple therapy [methotrexate (MTX), sulfasalazine (HCQ), and sulfasalazine (SSZ)] and TNF inhibitor (TNFi) plus MTX was similar in a previous clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].